David Einhorn Gain Therapeutics, Inc. Call Options Transaction History
Greenlight Capital Inc
- $1.97 Billion
- Q4 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
39Shares Held
4.47MCall Options Held
37.9KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.3 Million0.0% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.09 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$1.03 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA290KShares$557,6870.0% of portfolio
-
Marshall Wace, LLP London, X0276KShares$530,7510.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $22.8M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...